Metastatic Colorectal Cancer - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035

Metastatic Colorectal Cancer Market Outlook

Thelansis's "Metastatic Colorectal Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Metastatic Colorectal Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Metastatic Colorectal Cancer Overview

Metastatic colorectal cancer (mCRC), or Stage IV colorectal cancer, occurs when malignant cells originating in the colon or rectum spread to distant organs-most commonly the liver and lungs, and less frequently the peritoneum, brain, and bones. This metastatic progression is the primary driver of mortality in colorectal cancer.

While curative outcomes remain limited in advanced disease, therapeutic advancements have significantly improved overall survival and quality of life. Treatment is highly personalized and guided by tumor biology, molecular profile, and line of therapy, incorporating combinations of:

• Chemotherapy (FOLFOX, FOLFIRI-based regimens)
• Targeted therapies (EGFR inhibitors, VEGF inhibitors, BRAF inhibitors)
• Immunotherapies (particularly in MSI-H/dMMR populations)

In select patients, metastasectomy and liver-directed therapies (ablation, embolization) play a critical role in disease control and potential long-term remission.

Key Highlights

• mCRC represents a high-burden oncology segment, with a substantial proportion of colorectal cancer patients progressing to metastatic disease.
• The drug-treatable patient population remains large and growing, supported by increasing diagnosis rates and improved survival outcomes.
• Treatment paradigm is highly biomarker-driven, with segmentation based on: Tumor sidedness (left vs right) & Molecular status (RAS/BRAF mutations, MSI status)
• RAS mutations account for 45-50% of patients, while BRAF mutations (8-10%) represent a smaller but high-risk subgroup.
• Treatment is structured across multiple lines:
• 1st line: chemo + targeted therapy (EGFR/VEGF)
• 2nd line: therapy switch based on resistance patterns
• 3rd/4th line: later-line targeted agents and salvage therapies

Market Overview

• The mCRC market is valued at $4.3Bn in 2025, projected to reach $6.1Bn by 2035, reflecting a CAGR of 3.5-4%.
• Market growth is driven by: Increasing drug-treatable population (87K to 91K patients), Expanded use of targeted therapies and biologics, Improved treatment sequencing across multiple lines

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard/report will cost USD 1,750 per country

Companies Mentioned

• Mirati Therapeutics Inc.
• Buzzard Pharmaceuticals
• Parabilis Medicines, Inc.
• Astellas Pharma Inc
• Mirror Biologics, Inc.
• Shanghai Kechow Pharma, Inc.
• Suzhou Teligene Ltd.
• AstraZeneca
• Novartis Pharmaceuticals
• Carina Biotech Limited
• Treos Bio Limited
• Cardiff Oncology
• Alethia Biotherapeutics
• Shanghai EpimAb Biotherapeutics Co., Ltd.
• AbbVie
• Hoffmann-La Roche
• Menarini Group
• Akeso
• Riboscience, LLC.
• Amgen
• Qilu Pharmaceutical Co., Ltd.
• Pfizer
• BioNTech SE
• Arcus Biosciences, Inc.
• BeyondBio Inc.
• Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Agenus Inc.
• Bristol-Myers Squibb
• Taizhou Mabtech Pharmaceutical Co.,Ltd
• Incyte Biosciences International
• Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
• Hutchison Medipharma Limited
• Hansoh BioMedical R&D Company
• Jiangsu Simcere Pharmaceutical Co., Ltd.
• Luye Pharma Group Ltd.
• Shanghai JMT-Bio Inc.
• Summit Therapeutics
• Erasca, Inc.
• STCube, Inc.
• CytoDyn, Inc.
• Anbogen Therapeutics, Inc.
• Isofol Medical AB
• MedImmune LLC
• Beijing Biotech
• Vedanta Biosciences, Inc.
• Pierre Fabre Medicament
• Compass Therapeutics
• Amal Therapeutics
• MedPacto, Inc.
• PureTech
• IDEAYA Biosciences
• Wugen, Inc.
• Stingray Therapeutics
• Evopoint Biosciences Inc.